Boston Children's Hospital
childrenshospital.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
601
Active
175
Phase 3
24
Total enrollment
227,971
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| low bile acid binding blenderized diet | — | — | — | — | 3 | ||
| high bile acid binding blenderized diet | — | — | — | — | 3 | ||
| Famotidine | — | — | — | — | — | 2 | |
| oral oxycodone | — | — | — | — | — | 1 | |
| amino acid based formula | — | — | — | — | — | 1 | |
| Skin Cleanser Combination No.1 | — | — | — | — | — | 1 | |
| methylprednisolone acetate and lidocaine | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Prucalopride | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| liquid oxycodone | — | — | — | — | — | 1 | |
| methylphenidate HCl | — | — | — | — | — | 1 | |
| Mixed amphetamine salts extended release | — | — | — | — | — | 1 | |
| Dexmedetomidine (IV) 0.5 mcg/kg | — | — | — | — | — | 1 | |
| Propofol (IV) 2-4 mg/kg | — | — | — | — | — | 1 | |
| Dexmedetomidine (IV) 1 mcg/kg | — | — | — | — | — | 1 | |
| Propofol (IV) 1-2 mg/kg | — | — | — | — | — | 1 | |
| Propofol (IV) Infusion 250 mcg/kg/min | — | — | — | — | — | 1 | |
| Propofol (IV) Infusion 150 mcg/kg/min | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | 3 | ||
| Fludarabine | — | — | — | — | 2 | ||
| Ketamine hydrochloride | — | — | — | — | — | 2 | |
| Mycophenolate mofetil | — | — | — | — | 2 | ||
| Cyclosporine | — | — | — | — | — | 2 | |
| Methotrexate | — | — | — | — | 2 | ||
| horse anti-thymocyte globulin | — | — | — | — | — | 1 | |
| rabbit anti-thymocyte globulin | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Everolimus blinded oral | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 1 | |
| Oxcarbazepine | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | — | 3 | |
| Omalizumab | — | — | — | — | 3 | ||
| Metformin Hydrochloride | — | — | — | — | — | 1 | |
| Everolimus and lonafarnib | — | — | — | — | — | 1 | |
| alemtuzumab | — | — | — | — | — | 1 | |
| Cyclosporins | — | — | — | — | — | 1 | |
| Valproate | — | — | — | — | — | 1 | |
| Interleukin-2 (aldesleukin). | — | — | — | — | — | 1 |
17 more active programs hidden
Next readouts
- 2023-04-17
- 2026-05
- 2026-06
- 2026-06
- 2026-08
- 2026-08-01
- 2026-12
- 2026-12
- 2026-12
- 2026-12-31
Top conditions
- Congenital Heart Disease25
- Obesity16
- Asthma16
- Cystic Fibrosis14
- Autism Spectrum Disorder13
- Alcohol Abuse10
- Epilepsy9
- Anesthesia9
Frequently asked questions about Boston Children's Hospital
- How many clinical trials does Boston Children's Hospital have on ClinicalTrials.gov?
- Boston Children's Hospital is listed as the lead sponsor on 601 clinical trials in ClinicalTrials.gov, 175 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boston Children's Hospital's trials are in Phase 3?
- 24 of Boston Children's Hospital's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does Boston Children's Hospital focus on?
- Boston Children's Hospital's most-studied conditions on ClinicalTrials.gov are Congenital Heart Disease, Obesity, Asthma, Cystic Fibrosis, Autism Spectrum Disorder.
- When are Boston Children's Hospital's next clinical trial readouts?
- Boston Children's Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score”, expected around 2023-04-17.